Alzheimer’s disease (AD) presents a significant challenge to therapeutic interventions, necessitating the exploration of innovative strategies to manage its complex pathology. This study explores the relationship between autophagy and Transcription factor EB (TFEB) as a potential avenue for AD treatment. We demonstrate the therapeutic potential of TFEB in mitigating AD pathology by enhancing autophagy. Our strategy employs exosomes as vehicles for the targeted and efficient delivery of TFEB to affected cells. Exosomes, small extracellular vesicles, are recognized for their ability to cross biological barriers and deliver therapeutic agents to recipient cells. By loading exosomes with TFEB, we investigate their effect on autophagy induction and subsequent reduction of AD-related abnormalities. Our results reveal that TFEB-loaded exosomes effectively enhance autophagic activity, leading to a decrease in amyloid plaques and an improvement in cognitive functions in AD models. The use of exosomes for the targeted delivery of TFEB offers a novel and promising therapeutic approach to address AD pathology. In conclusion, our study highlights the therapeutic potential of TFEB in AD, focusing on its role in enhancing autophagic processes for the removal of amyloid plaques. The innovative application of exosomes as a delivery mechanism for TFEB underscores the translational potential of this strategy. This research contributes to the understanding of AD pathology and opens avenue for the development of targeted and effective treatments for neurodegenerative disorders.